Skip to search formSkip to main contentSkip to account menu

rituximab/yttrium Y 90 ibritumomab tiuxetan

Known as: IDEC-Y2B8/MOAB IDEC-C2B8 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2005
Review
2005
The clinical application of rituximab (chimeric mouse anti-human CD20 mAb, Rituxan, IDEC-C2B8), alone and/or combined with… 
2005
2005
PurposeThe aim of this study was to evaluate the safety, toxicity and therapeutic response of non-myeloablative… 
2001
2001
Mantle cell lymphoma (MCL) has a poor prognosis without cure; the median overall survival ranges only from 3 to 4 years… 
Highly Cited
2000
Highly Cited
2000
Rituximab (IDEC-C2B8, Mabthera(R)) is a chimeric (human-mouse) monoclonal antibody (MoAb) against the B-cell specific CD20… 
Highly Cited
2000
Highly Cited
2000
Abstract.Dosimetry studies in patients with non-Hodgkin’s lymphoma were performed to estimate the radiation absorbed dose to… 
Highly Cited
1998
Highly Cited
1998
BACKGROUND In clinical trials in the USA, IDEC-C2B8 (a mouse-human chimeric anti-CD20 monoclonal antibody) has demonstrated high… 
Highly Cited
1998
Highly Cited
1998
SummaryIn this report we present a patient with B-cell chronic lymphocytic leukemia who developed an acute tumor lysis syndrome… 
Highly Cited
1998
Highly Cited
1998
Treatment with IDEC‐C2B8 (C2B8), the chimeric anti‐CD20 antibody, was shown in a phase I‐II study to be very effective for the… 
Review
1998
Review
1998
Rituximab (IDEC-C2B8 [Rituxan]) is a chimeric anti-CD20 monoclonal antibody (MoAb) that was recently approved by the FDA for the… 
Highly Cited
1997
Highly Cited
1997
IDEC-C2B8 is a chimeric monoclonal antibody (MoAb) directed against the B-cell-specific antigen CD20 expressed on non-Hodgkin's…